Wei‐Yu Kao

机构：Taipei Medical University Hospital, Taipei Medical University · ORCID：0000-0002-5506-4293

发表论文 105 篇 · 总被引 1922 次 · h-index 24

代表论文

Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection (2024 · Journal of Hepatology · 被引 34)
Machine Learning Models for Predicting Significant Liver Fibrosis in Patients with Severe Obesity and Nonalcoholic Fatty Liver Disease (2024 · Obesity Surgery · 被引 13)
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection (2025 · Alimentary Pharmacology & Therapeutics · 被引 12)
High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease (2025 · Clinical and Molecular Hepatology · 被引 9)
Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma (2025 · Journal of the Formosan Medical Association · 被引 7)
The association between proton‐pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy (2024 · Journal of Gastroenterology and Hepatology · 被引 6)